Dr. Harrison explains, “A FibroScan-based score combining liver stiffness, controlled attenuation parameter (CAP™) and aspartate aminotransferase (AST) can efficiently screen for presence of at-risk fibrotic NASH. This non-invasive test is documented to quickly and cost effectively provide a quantitative assessment of liver stiffness and fat and can accurately identify patients eligible for potential pharmacologic therapy.”
He says this meeting furthers the worldwide understanding of liver research, enhances the clinical practice of liver disorders and educates those interested in hepatology. He points to over 2,000 peer-reviewed research publications which position FibroScan as the most widely studied tool for point of care liver assessment.
During the Congress, Dr. Harrison will also present seminal work on the prospective liver biopsy-based prevalence of NAFLD/NASH among a large middle-aged population, utilizing FibroScan, LiverMultiscan and magnetic resonance elastography (MRE). Additionally, he will present findings related to predicting the severity of hepatic steatosis and fibrosis by transient elastography and magnetic resonance imaging (MRI)-based techniques in adult patients with suspected NAFLD.
Attendees will hear an oral presentation by Dr. Boursier on April 14, 2019, showing external validation in NAFLD cohorts of a FibroScan-based score combining liver stiffness via VCTE™, CAP™ and AST to identify patients with active NASH (NAS>=4) and significant fibrosis (F>=2). The results of his study show that a simple score based on FibroScan LSM, CAP and AST demonstrated good performance in all NAFLD cohorts.
“I want to emphasize that FibroScan could be used in specialty and primary care settings to efficiently screen patients with active NASH (NAS≥4) and significant fibrosis (F≥2) for drug trials, as well as to identify patients eligible for treatment when the drugs currently evaluated in clinical trials will become available on the market” says Dr. Boursier.
Other presentations include:
- “Effectively reducing screen failure rate in a NAFLD clinical trial using a FibroScan based score combining liver stiffness, CAP and AST.” The Fibroscan-based score identified optimal cut-offs to significantly reduce screen failure rate with an acceptable missed case rate.
- “Combination of FibroScan and FibroMeter (FibroMeter VCTE) improves identification of patients with advanced fibrosis in patients with NAFLD.” FibroMeterVCTE performs well in the identification of patients with advanced fibrosis without compromising sensitivity.